A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.
Advanced Pancreatic Cancer
DRUG: JS107|COMBINATION_PRODUCT: JS107 combination with Toripalimab
MTD, Determine maximum tolerated dose (MTD, if possible), Up to approximately 12 months from first patient in.|RP2D, Recommended phase II dose (RP2D) for JS107 monotherapy and combination therapy, Up to approximately 24 months from first patient in.
Drug concentrations in plasma, Drug concentrations in individual subjects at different time points after dosing, Up to approximately 24 months from first patient in.|Immunogenicity, Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (Nab), titer of ADA positive samples, Up to approximately 24 months from first patient in.|ORR, Objective response rate (ORR) was assessed based on RECIST V1.1 criteria, Up to approximately 24 months from first patient in.
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.